Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
3,628
archived clinical trials in
Schizophrenia

Pharmacodynamic/Pharmacokinetic Study of AQW051 in Schizophrenia
A Single-dose, Placebo-controlled, Stratified, Randomized, Double-blind, Crossover to Study Pharmacodynamic Effects of AQW051 Followed by a 4-week Multiple-dose Safety and Tolerability in People With Chronic Stable Schizophrenia.
Status: Archived
John Umstead Hospital/Duke University
mi
from
Butner, NC
Pharmacodynamic/Pharmacokinetic Study of AQW051 in Schizophrenia
A Single-dose, Placebo-controlled, Stratified, Randomized, Double-blind, Crossover to Study Pharmacodynamic Effects of AQW051 Followed by a 4-week Multiple-dose Safety and Tolerability in People With Chronic Stable Schizophrenia.
Status: Archived
Updated: 1/1/1970
John Umstead Hospital/Duke University
mi
from
Butner, NC
Effects of Eszopiclone on Sleep-dependent Learning in Schizophrenia
Effects of Eszopiclone on Sleep-dependent Learning in Schizophrenia
Status: Archived
Massachusetts General Hospital
mi
from
Boston, MA
Effects of Eszopiclone on Sleep-dependent Learning in Schizophrenia
Effects of Eszopiclone on Sleep-dependent Learning in Schizophrenia
Status: Archived
Updated: 1/1/1970
Massachusetts General Hospital
mi
from
Boston, MA
Oxytocin and Social Cognition in Schizophrenia
Oxytocin and Social Cognition in Schizophrenia
Status: Archived
Maryland Psychiatric Research Center
mi
from
Baltimore, MD
Oxytocin and Social Cognition in Schizophrenia
Oxytocin and Social Cognition in Schizophrenia
Status: Archived
Updated: 1/1/1970
Maryland Psychiatric Research Center
mi
from
Baltimore, MD
Using Cognitive Training to Improve Employment Programs for People With Severe Mental Illnesses
Cognitive Training to Improve Work Outcomes in Severe Mental Illness
Status: Archived
UC San Diego Medical Center
mi
from
San Diego, CA
Using Cognitive Training to Improve Employment Programs for People With Severe Mental Illnesses
Cognitive Training to Improve Work Outcomes in Severe Mental Illness
Status: Archived
Updated: 1/1/1970
UC San Diego Medical Center
mi
from
San Diego, CA
Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study
Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study
Status: Archived
University of North Carolina Hospital at Chapel Hill
mi
from
Chapel Hill, NC
Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study
Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study
Status: Archived
Updated: 1/1/1970
University of North Carolina Hospital at Chapel Hill
mi
from
Chapel Hill, NC
Once Weekly D-cycloserine for Schizophrenia
Effects of Weekly Dosing of D-cycloserine on Cognitive Function in Individuals With Schizophrenia.
Status: Archived
Massachusetts General Hospital
mi
from
Boston, MA
Once Weekly D-cycloserine for Schizophrenia
Effects of Weekly Dosing of D-cycloserine on Cognitive Function in Individuals With Schizophrenia.
Status: Archived
Updated: 1/1/1970
Massachusetts General Hospital
mi
from
Boston, MA
Study of Amantadine for Risperidone Consta or Paliperidone Treated Patients to Decrease Prolactin Elevation
Amantadine Addition to Paliperidone ER or Risperidone Consta Therapy for Prolactin Elevation
Status: Archived
Freedom Trail Clinic, Massachusetts General Hospital
mi
from
Boston, MA
Study of Amantadine for Risperidone Consta or Paliperidone Treated Patients to Decrease Prolactin Elevation
Amantadine Addition to Paliperidone ER or Risperidone Consta Therapy for Prolactin Elevation
Status: Archived
Updated: 1/1/1970
Freedom Trail Clinic, Massachusetts General Hospital
mi
from
Boston, MA
The Effects AZD8529 on Cognition and Negative Symptoms in Schizophrenics
A Single Center, Double-Blind, Randomized, Placebo-Controlled, Two-Period Crossover Study to Access an Early Signal of Efficacy for Cognition and Negative Symptoms With AZD8529 in Patients With Schizophrenia
Status: Archived
Clinical Research Facility
mi
from
Allentown, PA
The Effects AZD8529 on Cognition and Negative Symptoms in Schizophrenics
A Single Center, Double-Blind, Randomized, Placebo-Controlled, Two-Period Crossover Study to Access an Early Signal of Efficacy for Cognition and Negative Symptoms With AZD8529 in Patients With Schizophrenia
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Allentown, PA
Effectiveness and Safety of Flexible Doses of Paliperidone Prolonged Release in Adolescent Patients With Schizophrenia
A Randomized, Multicenter, Double-blind, Active-controlled, Flexible-dose, Parallel-group Study of the Efficacy and Safety of Prolonged Release Paliperidone for the Treatment of Symptoms of Schizophrenia in Adolescent Subjects, 12 to 17 Years of Age
Status: Archived
Clinical Trial Facility
mi
from
Birmingham, AL
Effectiveness and Safety of Flexible Doses of Paliperidone Prolonged Release in Adolescent Patients With Schizophrenia
A Randomized, Multicenter, Double-blind, Active-controlled, Flexible-dose, Parallel-group Study of the Efficacy and Safety of Prolonged Release Paliperidone for the Treatment of Symptoms of Schizophrenia in Adolescent Subjects, 12 to 17 Years of Age
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Birmingham, AL
Effectiveness and Safety of Flexible Doses of Paliperidone Prolonged Release in Adolescent Patients With Schizophrenia
A Randomized, Multicenter, Double-blind, Active-controlled, Flexible-dose, Parallel-group Study of the Efficacy and Safety of Prolonged Release Paliperidone for the Treatment of Symptoms of Schizophrenia in Adolescent Subjects, 12 to 17 Years of Age
Status: Archived
Clinical Trial Facility
mi
from
Santa Clara, CA
Effectiveness and Safety of Flexible Doses of Paliperidone Prolonged Release in Adolescent Patients With Schizophrenia
A Randomized, Multicenter, Double-blind, Active-controlled, Flexible-dose, Parallel-group Study of the Efficacy and Safety of Prolonged Release Paliperidone for the Treatment of Symptoms of Schizophrenia in Adolescent Subjects, 12 to 17 Years of Age
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Santa Clara, CA
Effectiveness and Safety of Flexible Doses of Paliperidone Prolonged Release in Adolescent Patients With Schizophrenia
A Randomized, Multicenter, Double-blind, Active-controlled, Flexible-dose, Parallel-group Study of the Efficacy and Safety of Prolonged Release Paliperidone for the Treatment of Symptoms of Schizophrenia in Adolescent Subjects, 12 to 17 Years of Age
Status: Archived
Clinical Trial Facility
mi
from
Washington,
Effectiveness and Safety of Flexible Doses of Paliperidone Prolonged Release in Adolescent Patients With Schizophrenia
A Randomized, Multicenter, Double-blind, Active-controlled, Flexible-dose, Parallel-group Study of the Efficacy and Safety of Prolonged Release Paliperidone for the Treatment of Symptoms of Schizophrenia in Adolescent Subjects, 12 to 17 Years of Age
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Washington,
Effectiveness and Safety of Flexible Doses of Paliperidone Prolonged Release in Adolescent Patients With Schizophrenia
A Randomized, Multicenter, Double-blind, Active-controlled, Flexible-dose, Parallel-group Study of the Efficacy and Safety of Prolonged Release Paliperidone for the Treatment of Symptoms of Schizophrenia in Adolescent Subjects, 12 to 17 Years of Age
Status: Archived
Clinical Trial Facility
mi
from
Atlanta, GA
Effectiveness and Safety of Flexible Doses of Paliperidone Prolonged Release in Adolescent Patients With Schizophrenia
A Randomized, Multicenter, Double-blind, Active-controlled, Flexible-dose, Parallel-group Study of the Efficacy and Safety of Prolonged Release Paliperidone for the Treatment of Symptoms of Schizophrenia in Adolescent Subjects, 12 to 17 Years of Age
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Atlanta, GA
Effectiveness and Safety of Flexible Doses of Paliperidone Prolonged Release in Adolescent Patients With Schizophrenia
A Randomized, Multicenter, Double-blind, Active-controlled, Flexible-dose, Parallel-group Study of the Efficacy and Safety of Prolonged Release Paliperidone for the Treatment of Symptoms of Schizophrenia in Adolescent Subjects, 12 to 17 Years of Age
Status: Archived
Clinical Trial Facility
mi
from
Metairie, LA
Effectiveness and Safety of Flexible Doses of Paliperidone Prolonged Release in Adolescent Patients With Schizophrenia
A Randomized, Multicenter, Double-blind, Active-controlled, Flexible-dose, Parallel-group Study of the Efficacy and Safety of Prolonged Release Paliperidone for the Treatment of Symptoms of Schizophrenia in Adolescent Subjects, 12 to 17 Years of Age
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Metairie, LA
InORS - International Observational Registry on Schizophrenia With Injectable Risperidone and Oral Antipsychotics
Observational, Non-interventional Registry to Assess Medication Usage Patterns in Clinical Routine Practice, in Subjects Receiving Antipsychotic Treatment With Risperidone Long Acting Injectable (Gluteal or Deltoid) or Oral Antipsychotics
Status: Archived
Clinical Trial Facility
mi
from
Birmingham, AL
InORS - International Observational Registry on Schizophrenia With Injectable Risperidone and Oral Antipsychotics
Observational, Non-interventional Registry to Assess Medication Usage Patterns in Clinical Routine Practice, in Subjects Receiving Antipsychotic Treatment With Risperidone Long Acting Injectable (Gluteal or Deltoid) or Oral Antipsychotics
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Birmingham, AL
Intensive Computerized Brain Training (ICBT) in Youth With Early Onset Schizophrenia and Schizoaffective (EOSS)
Intensive Computerized Brain Training in Early Onset Schizophrenia and Schizoaffective Disorder-Pilot Phase
Status: Archived
University of North Carolina Hospital at Chapel Hill
mi
from
Chapel Hill, NC
Intensive Computerized Brain Training (ICBT) in Youth With Early Onset Schizophrenia and Schizoaffective (EOSS)
Intensive Computerized Brain Training in Early Onset Schizophrenia and Schizoaffective Disorder-Pilot Phase
Status: Archived
Updated: 1/1/1970
University of North Carolina Hospital at Chapel Hill
mi
from
Chapel Hill, NC
Oxytocin Treatment of Schizophrenia
Oxytocin Treatment of Social Deficits and Paranoia in Schizophrenia
Status: Archived
University of North Carolina Hospital at Chapel Hill
mi
from
Chapel Hill, NC
Oxytocin Treatment of Schizophrenia
Oxytocin Treatment of Social Deficits and Paranoia in Schizophrenia
Status: Archived
Updated: 1/1/1970
University of North Carolina Hospital at Chapel Hill
mi
from
Chapel Hill, NC
Oxytocin Treatment of Schizophrenia
Oxytocin Treatment of Social Deficits and Paranoia in Schizophrenia
Status: Archived
Central Regional Hospital
mi
from
Raleigh, NC
Oxytocin Treatment of Schizophrenia
Oxytocin Treatment of Social Deficits and Paranoia in Schizophrenia
Status: Archived
Updated: 1/1/1970
Central Regional Hospital
mi
from
Raleigh, NC
Risk Perception in Drug-Dependent Adults With and Without Schizophrenia
Risk Perception in Drug-Dependent Adults With and Without Schizophrenia
Status: Archived
Maryland Psychiatric Research Center
mi
from
Baltimore, MD
Risk Perception in Drug-Dependent Adults With and Without Schizophrenia
Risk Perception in Drug-Dependent Adults With and Without Schizophrenia
Status: Archived
Updated: 1/1/1970
Maryland Psychiatric Research Center
mi
from
Baltimore, MD
An Observational Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children
Evaluation of Growth, Sexual Maturation, and Prolactin-Related Adverse Events in the Pediatric Population Exposed to Atypical Antipsychotic Drugs
Status: Archived
Clinical Trial Facility
mi
from
Santa Clara, CA
An Observational Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children
Evaluation of Growth, Sexual Maturation, and Prolactin-Related Adverse Events in the Pediatric Population Exposed to Atypical Antipsychotic Drugs
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Santa Clara, CA
An Observational Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children
Evaluation of Growth, Sexual Maturation, and Prolactin-Related Adverse Events in the Pediatric Population Exposed to Atypical Antipsychotic Drugs
Status: Archived
Clinical Trial Facility
mi
from
Denver, CO
An Observational Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children
Evaluation of Growth, Sexual Maturation, and Prolactin-Related Adverse Events in the Pediatric Population Exposed to Atypical Antipsychotic Drugs
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Denver, CO
An Observational Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children
Evaluation of Growth, Sexual Maturation, and Prolactin-Related Adverse Events in the Pediatric Population Exposed to Atypical Antipsychotic Drugs
Status: Archived
Clinical Trial Facility
mi
from
Celebration, FL
An Observational Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children
Evaluation of Growth, Sexual Maturation, and Prolactin-Related Adverse Events in the Pediatric Population Exposed to Atypical Antipsychotic Drugs
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Celebration, FL
An Observational Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children
Evaluation of Growth, Sexual Maturation, and Prolactin-Related Adverse Events in the Pediatric Population Exposed to Atypical Antipsychotic Drugs
Status: Archived
Clinical Trial Facility
mi
from
Atlanta, GA
An Observational Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children
Evaluation of Growth, Sexual Maturation, and Prolactin-Related Adverse Events in the Pediatric Population Exposed to Atypical Antipsychotic Drugs
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Atlanta, GA
An Observational Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children
Evaluation of Growth, Sexual Maturation, and Prolactin-Related Adverse Events in the Pediatric Population Exposed to Atypical Antipsychotic Drugs
Status: Archived
Clinical Trial Facility
mi
from
Centralia, IL
An Observational Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children
Evaluation of Growth, Sexual Maturation, and Prolactin-Related Adverse Events in the Pediatric Population Exposed to Atypical Antipsychotic Drugs
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Centralia, IL
An Observational Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children
Evaluation of Growth, Sexual Maturation, and Prolactin-Related Adverse Events in the Pediatric Population Exposed to Atypical Antipsychotic Drugs
Status: Archived
Clinical Trial Facility
mi
from
Jeffersonville, IN
An Observational Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children
Evaluation of Growth, Sexual Maturation, and Prolactin-Related Adverse Events in the Pediatric Population Exposed to Atypical Antipsychotic Drugs
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Jeffersonville, IN
An Observational Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children
Evaluation of Growth, Sexual Maturation, and Prolactin-Related Adverse Events in the Pediatric Population Exposed to Atypical Antipsychotic Drugs
Status: Archived
Clinical Trial Facility
mi
from
Boston, MA
An Observational Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children
Evaluation of Growth, Sexual Maturation, and Prolactin-Related Adverse Events in the Pediatric Population Exposed to Atypical Antipsychotic Drugs
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Boston, MA
An Observational Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children
Evaluation of Growth, Sexual Maturation, and Prolactin-Related Adverse Events in the Pediatric Population Exposed to Atypical Antipsychotic Drugs
Status: Archived
Clinical Trial Facility
mi
from
Albany, NY
An Observational Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children
Evaluation of Growth, Sexual Maturation, and Prolactin-Related Adverse Events in the Pediatric Population Exposed to Atypical Antipsychotic Drugs
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Albany, NY
An Observational Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children
Evaluation of Growth, Sexual Maturation, and Prolactin-Related Adverse Events in the Pediatric Population Exposed to Atypical Antipsychotic Drugs
Status: Archived
Clinical Trial Facility
mi
from
Lima, OH
An Observational Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children
Evaluation of Growth, Sexual Maturation, and Prolactin-Related Adverse Events in the Pediatric Population Exposed to Atypical Antipsychotic Drugs
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Lima, OH
A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms
A 17-Week, Phase 2, Multicenter, Randomized, Double-Blind Study of Treatment With LY2140023 Combined With Standard of Care Compared to Placebo Combined With Standard of Care in the Treatment of Patients With Prominent Negative Symptoms of Schizophrenia
Status: Archived
Dana-Farber / Harvard Cancer Center
mi
from
Boston, MA
A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms
A 17-Week, Phase 2, Multicenter, Randomized, Double-Blind Study of Treatment With LY2140023 Combined With Standard of Care Compared to Placebo Combined With Standard of Care in the Treatment of Patients With Prominent Negative Symptoms of Schizophrenia
Status: Archived
Updated: 1/1/1970
Dana-Farber / Harvard Cancer Center
mi
from
Boston, MA
A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms
A 17-Week, Phase 2, Multicenter, Randomized, Double-Blind Study of Treatment With LY2140023 Combined With Standard of Care Compared to Placebo Combined With Standard of Care in the Treatment of Patients With Prominent Negative Symptoms of Schizophrenia
Status: Archived
Clinical Research Facility
mi
from
Washington,
A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms
A 17-Week, Phase 2, Multicenter, Randomized, Double-Blind Study of Treatment With LY2140023 Combined With Standard of Care Compared to Placebo Combined With Standard of Care in the Treatment of Patients With Prominent Negative Symptoms of Schizophrenia
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Washington,
A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms
A 17-Week, Phase 2, Multicenter, Randomized, Double-Blind Study of Treatment With LY2140023 Combined With Standard of Care Compared to Placebo Combined With Standard of Care in the Treatment of Patients With Prominent Negative Symptoms of Schizophrenia
Status: Archived
Maine Center for Cancer Medicine and Blood Disorders - Scarborough
mi
from
Scarborough, ME
A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms
A 17-Week, Phase 2, Multicenter, Randomized, Double-Blind Study of Treatment With LY2140023 Combined With Standard of Care Compared to Placebo Combined With Standard of Care in the Treatment of Patients With Prominent Negative Symptoms of Schizophrenia
Status: Archived
Updated: 1/1/1970
Maine Center for Cancer Medicine and Blood Disorders - Scarborough
mi
from
Scarborough, ME
A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms
A 17-Week, Phase 2, Multicenter, Randomized, Double-Blind Study of Treatment With LY2140023 Combined With Standard of Care Compared to Placebo Combined With Standard of Care in the Treatment of Patients With Prominent Negative Symptoms of Schizophrenia
Status: Archived
University of Vermont College of Medicine
mi
from
Burlington, VT
A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms
A 17-Week, Phase 2, Multicenter, Randomized, Double-Blind Study of Treatment With LY2140023 Combined With Standard of Care Compared to Placebo Combined With Standard of Care in the Treatment of Patients With Prominent Negative Symptoms of Schizophrenia
Status: Archived
Updated: 1/1/1970
University of Vermont College of Medicine
mi
from
Burlington, VT
A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms
A 17-Week, Phase 2, Multicenter, Randomized, Double-Blind Study of Treatment With LY2140023 Combined With Standard of Care Compared to Placebo Combined With Standard of Care in the Treatment of Patients With Prominent Negative Symptoms of Schizophrenia
Status: Archived
Clinical Research Facility
mi
from
Topeka, KA
A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms
A 17-Week, Phase 2, Multicenter, Randomized, Double-Blind Study of Treatment With LY2140023 Combined With Standard of Care Compared to Placebo Combined With Standard of Care in the Treatment of Patients With Prominent Negative Symptoms of Schizophrenia
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Topeka, KA
A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms
A 17-Week, Phase 2, Multicenter, Randomized, Double-Blind Study of Treatment With LY2140023 Combined With Standard of Care Compared to Placebo Combined With Standard of Care in the Treatment of Patients With Prominent Negative Symptoms of Schizophrenia
Status: Archived
Clinical Research Facility
mi
from
Alexandria, LA
A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms
A 17-Week, Phase 2, Multicenter, Randomized, Double-Blind Study of Treatment With LY2140023 Combined With Standard of Care Compared to Placebo Combined With Standard of Care in the Treatment of Patients With Prominent Negative Symptoms of Schizophrenia
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Alexandria, LA
A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms
A 17-Week, Phase 2, Multicenter, Randomized, Double-Blind Study of Treatment With LY2140023 Combined With Standard of Care Compared to Placebo Combined With Standard of Care in the Treatment of Patients With Prominent Negative Symptoms of Schizophrenia
Status: Archived
Clinical Research Facility
mi
from
Bridgewater, NJ
A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms
A 17-Week, Phase 2, Multicenter, Randomized, Double-Blind Study of Treatment With LY2140023 Combined With Standard of Care Compared to Placebo Combined With Standard of Care in the Treatment of Patients With Prominent Negative Symptoms of Schizophrenia
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Bridgewater, NJ
A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms
A 17-Week, Phase 2, Multicenter, Randomized, Double-Blind Study of Treatment With LY2140023 Combined With Standard of Care Compared to Placebo Combined With Standard of Care in the Treatment of Patients With Prominent Negative Symptoms of Schizophrenia
Status: Archived
Clinical Research Facility
mi
from
Brooklyn, NY
A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms
A 17-Week, Phase 2, Multicenter, Randomized, Double-Blind Study of Treatment With LY2140023 Combined With Standard of Care Compared to Placebo Combined With Standard of Care in the Treatment of Patients With Prominent Negative Symptoms of Schizophrenia
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Brooklyn, NY
A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms
A 17-Week, Phase 2, Multicenter, Randomized, Double-Blind Study of Treatment With LY2140023 Combined With Standard of Care Compared to Placebo Combined With Standard of Care in the Treatment of Patients With Prominent Negative Symptoms of Schizophrenia
Status: Archived
Clinical Research Facility
mi
from
Fort Worth, TX
A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms
A 17-Week, Phase 2, Multicenter, Randomized, Double-Blind Study of Treatment With LY2140023 Combined With Standard of Care Compared to Placebo Combined With Standard of Care in the Treatment of Patients With Prominent Negative Symptoms of Schizophrenia
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Fort Worth, TX
A Study in Schizophrenia Patients
A Phase 2, Multicenter, Double-Blind, Placebo-Controlled Comparator Study of 2 Doses of LY2140023 Versus Placebo in Patients With DSM-IV-TR Schizophrenia
Status: Archived
Dana-Farber / Harvard Cancer Center
mi
from
Boston, MA
A Study in Schizophrenia Patients
A Phase 2, Multicenter, Double-Blind, Placebo-Controlled Comparator Study of 2 Doses of LY2140023 Versus Placebo in Patients With DSM-IV-TR Schizophrenia
Status: Archived
Updated: 1/1/1970
Dana-Farber / Harvard Cancer Center
mi
from
Boston, MA
A Study in Schizophrenia Patients
A Phase 2, Multicenter, Double-Blind, Placebo-Controlled Comparator Study of 2 Doses of LY2140023 Versus Placebo in Patients With DSM-IV-TR Schizophrenia
Status: Archived
Clinical Research Facility
mi
from
Washington,
A Study in Schizophrenia Patients
A Phase 2, Multicenter, Double-Blind, Placebo-Controlled Comparator Study of 2 Doses of LY2140023 Versus Placebo in Patients With DSM-IV-TR Schizophrenia
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Washington,
A Study in Schizophrenia Patients
A Phase 2, Multicenter, Double-Blind, Placebo-Controlled Comparator Study of 2 Doses of LY2140023 Versus Placebo in Patients With DSM-IV-TR Schizophrenia
Status: Archived
Clinical Research Facility
mi
from
Miami, FL
A Study in Schizophrenia Patients
A Phase 2, Multicenter, Double-Blind, Placebo-Controlled Comparator Study of 2 Doses of LY2140023 Versus Placebo in Patients With DSM-IV-TR Schizophrenia
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Miami, FL
A Study in Schizophrenia Patients
A Phase 2, Multicenter, Double-Blind, Placebo-Controlled Comparator Study of 2 Doses of LY2140023 Versus Placebo in Patients With DSM-IV-TR Schizophrenia
Status: Archived
Aurora Memorial Hospital of Burlington
mi
from
Burlington, WI
A Study in Schizophrenia Patients
A Phase 2, Multicenter, Double-Blind, Placebo-Controlled Comparator Study of 2 Doses of LY2140023 Versus Placebo in Patients With DSM-IV-TR Schizophrenia
Status: Archived
Updated: 1/1/1970
Aurora Memorial Hospital of Burlington
mi
from
Burlington, WI
A Study in Schizophrenia Patients
A Phase 2, Multicenter, Double-Blind, Placebo-Controlled Comparator Study of 2 Doses of LY2140023 Versus Placebo in Patients With DSM-IV-TR Schizophrenia
Status: Archived
Maine Center for Cancer Medicine and Blood Disorders - Scarborough
mi
from
Scarborough, ME
A Study in Schizophrenia Patients
A Phase 2, Multicenter, Double-Blind, Placebo-Controlled Comparator Study of 2 Doses of LY2140023 Versus Placebo in Patients With DSM-IV-TR Schizophrenia
Status: Archived
Updated: 1/1/1970
Maine Center for Cancer Medicine and Blood Disorders - Scarborough
mi
from
Scarborough, ME
A Study in Schizophrenia Patients
A Phase 2, Multicenter, Double-Blind, Placebo-Controlled Comparator Study of 2 Doses of LY2140023 Versus Placebo in Patients With DSM-IV-TR Schizophrenia
Status: Archived
University of Vermont College of Medicine
mi
from
Burlington, VT
A Study in Schizophrenia Patients
A Phase 2, Multicenter, Double-Blind, Placebo-Controlled Comparator Study of 2 Doses of LY2140023 Versus Placebo in Patients With DSM-IV-TR Schizophrenia
Status: Archived
Updated: 1/1/1970
University of Vermont College of Medicine
mi
from
Burlington, VT
A Study in Schizophrenia Patients
A Phase 2, Multicenter, Double-Blind, Placebo-Controlled Comparator Study of 2 Doses of LY2140023 Versus Placebo in Patients With DSM-IV-TR Schizophrenia
Status: Archived
Clinical Research Facility
mi
from
Alexandria, LA
A Study in Schizophrenia Patients
A Phase 2, Multicenter, Double-Blind, Placebo-Controlled Comparator Study of 2 Doses of LY2140023 Versus Placebo in Patients With DSM-IV-TR Schizophrenia
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Alexandria, LA
A Study in Schizophrenia Patients
A Phase 2, Multicenter, Double-Blind, Placebo-Controlled Comparator Study of 2 Doses of LY2140023 Versus Placebo in Patients With DSM-IV-TR Schizophrenia
Status: Archived
Clinical Research Facility
mi
from
Picayune, MS
A Study in Schizophrenia Patients
A Phase 2, Multicenter, Double-Blind, Placebo-Controlled Comparator Study of 2 Doses of LY2140023 Versus Placebo in Patients With DSM-IV-TR Schizophrenia
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Picayune, MS
A Study in Schizophrenia Patients
A Phase 2, Multicenter, Double-Blind, Placebo-Controlled Comparator Study of 2 Doses of LY2140023 Versus Placebo in Patients With DSM-IV-TR Schizophrenia
Status: Archived
Hartford Hospital- The Institute of Living
mi
from
Hartford, CT
A Study in Schizophrenia Patients
A Phase 2, Multicenter, Double-Blind, Placebo-Controlled Comparator Study of 2 Doses of LY2140023 Versus Placebo in Patients With DSM-IV-TR Schizophrenia
Status: Archived
Updated: 1/1/1970
Hartford Hospital- The Institute of Living
mi
from
Hartford, CT
A Study in Schizophrenia Patients
A Phase 2, Multicenter, Double-Blind, Placebo-Controlled Comparator Study of 2 Doses of LY2140023 Versus Placebo in Patients With DSM-IV-TR Schizophrenia
Status: Archived
Clinical Research Facility
mi
from
Brooklyn, NY
A Study in Schizophrenia Patients
A Phase 2, Multicenter, Double-Blind, Placebo-Controlled Comparator Study of 2 Doses of LY2140023 Versus Placebo in Patients With DSM-IV-TR Schizophrenia
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Brooklyn, NY
A Study in Schizophrenia Patients
A Phase 2, Multicenter, Double-Blind, Placebo-Controlled Comparator Study of 2 Doses of LY2140023 Versus Placebo in Patients With DSM-IV-TR Schizophrenia
Status: Archived
Clinical Research Facility
mi
from
Cincinnati, OH
A Study in Schizophrenia Patients
A Phase 2, Multicenter, Double-Blind, Placebo-Controlled Comparator Study of 2 Doses of LY2140023 Versus Placebo in Patients With DSM-IV-TR Schizophrenia
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Cincinnati, OH
A Study in Schizophrenia Patients
A Phase 2, Multicenter, Double-Blind, Placebo-Controlled Comparator Study of 2 Doses of LY2140023 Versus Placebo in Patients With DSM-IV-TR Schizophrenia
Status: Archived
New York Methodist Hospital
mi
from
Brooklyn, NY
A Study in Schizophrenia Patients
A Phase 2, Multicenter, Double-Blind, Placebo-Controlled Comparator Study of 2 Doses of LY2140023 Versus Placebo in Patients With DSM-IV-TR Schizophrenia
Status: Archived
Updated: 1/1/1970
New York Methodist Hospital
mi
from
Brooklyn, NY
A Study in Schizophrenia Patients
A Phase 2, Multicenter, Double-Blind, Placebo-Controlled Comparator Study of 2 Doses of LY2140023 Versus Placebo in Patients With DSM-IV-TR Schizophrenia
Status: Archived
Clinical Research Facility
mi
from
Chattanooga, TN
A Study in Schizophrenia Patients
A Phase 2, Multicenter, Double-Blind, Placebo-Controlled Comparator Study of 2 Doses of LY2140023 Versus Placebo in Patients With DSM-IV-TR Schizophrenia
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Chattanooga, TN
A Study in Schizophrenia Patients
A Phase 2, Multicenter, Double-Blind, Placebo-Controlled Comparator Study of 2 Doses of LY2140023 Versus Placebo in Patients With DSM-IV-TR Schizophrenia
Status: Archived
Clinical Research Facility
mi
from
Fort Worth, TX
A Study in Schizophrenia Patients
A Phase 2, Multicenter, Double-Blind, Placebo-Controlled Comparator Study of 2 Doses of LY2140023 Versus Placebo in Patients With DSM-IV-TR Schizophrenia
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Fort Worth, TX